Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
6 clinical trials · Condition
◉ Watch Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04665765) | City of Hope Medical Center | 2021-01-18 |
| CD19-Specific T Cells Post AlloSCT (NCT03579888) | M.D. Anderson Cancer Center | 2020-06-26 |
| Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy (NCT04409314) | University of California, San Francisco | 2020-04-16 |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma (NCT04205838) | Jonsson Comprehensive Cancer Center | 2020-03-04 |
| Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. (NCT03150329) | City of Hope Medical Center | 2017-07-18 |
Track Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.